Track the Telix Pharmaceuticals Limited share price and the full directors' dealings record of the company, a publicly traded company based in Australia. Shares are quoted on the AU market, under the oversight of ASX. Operating in the Health Care sector, Telix Pharmaceuticals Limited has recorded 13 reports. Market capitalisation: €5.7bn. The latest transaction was reported on 8 July 2026 (Change in Substantial Holding). Among the most active insiders: There was a change in the interests of the. The full history is free.
13
Insider Decl.
n/a
Thresholds
€8
1 ops.
Buy Volume
€26
4 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Telix Pharmaceuticals Limited Strong Buy (bullish), based on 13 analysts. Average price target: A$23.48.
24Σ signal
Buys €8€26 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,638 of 29,063 companies
35.0
score / 100
Value
32
Quality
38
FCF yld-1.2%
Earn yld-0.1%
EV/EBITDA·
ROE7.4%
Gross mgn53%
Net mgn-0.9%
Debt/EBITDA13.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Telix Pharmaceuticals Limited es una empresa biofarmacéutica centrada en el desarrollo de terapias dirigidas para el cáncer. Se especializa en radiofármacos y medicina de precisión.